Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ling Cen

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Molecular Cancer Therapeutics|October 7, 2015
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous SystemKaren E Parrish, Ling Cen, James Murray, et al.
Blood|April 27, 2022
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaMichael D Jain, Bachisio Ziccheddu, Caroline A Coughlin, et al.
Scientific Reports|November 18, 2023
Modeling phenotypic heterogeneity towards evolutionarily inspired osteosarcoma therapyDarcy L Welch, Brooke L Fridley, Ling Cen, et al.
The Journal of Investigative Dermatology|June 20, 2020
Noninvasive Assessment of Epidermal Genomic Markers of UV Exposure in SkinElnara Muradova, Nishit Patel, Brittney Sell, et al.
Nature Communications|August 17, 2019
Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repressionYu Cao, Jimena Trillo-Tinoco, Rosa A Sierra, et al.
Nature Communications|March 22, 2019
ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repressionYu Cao, Jimena Trillo-Tinoco, Rosa A Sierra, et al.
Cancer Immunology Research|April 18, 2025
Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer CellsGanesan Ramamoorthi, Marie Catherine Lee, Carly M Farrell, et al.
Nature Communications|May 25, 2026
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trialJeffrey S Johnson, Justin W Miller, Firas Hatoum, et al.
Blood Cancer Discovery|April 16, 2021
TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemiaSeongseok Yun, Nicole D Vincelette, Xiaoqing Yu, et al.
Journal of the National Cancer Institute|November 29, 2015
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaShiv K Gupta, Sani H Kizilbash, Brett L Carlson, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Molecular Cancer Therapeutics|October 7, 2015
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous SystemKaren E Parrish, Ling Cen, James Murray, et al.
Blood|April 27, 2022
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaMichael D Jain, Bachisio Ziccheddu, Caroline A Coughlin, et al.
Scientific Reports|November 18, 2023
Modeling phenotypic heterogeneity towards evolutionarily inspired osteosarcoma therapyDarcy L Welch, Brooke L Fridley, Ling Cen, et al.
The Journal of Investigative Dermatology|June 20, 2020
Noninvasive Assessment of Epidermal Genomic Markers of UV Exposure in SkinElnara Muradova, Nishit Patel, Brittney Sell, et al.
Nature Communications|August 17, 2019
Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repressionYu Cao, Jimena Trillo-Tinoco, Rosa A Sierra, et al.
Nature Communications|March 22, 2019
ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repressionYu Cao, Jimena Trillo-Tinoco, Rosa A Sierra, et al.
Cancer Immunology Research|April 18, 2025
Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer CellsGanesan Ramamoorthi, Marie Catherine Lee, Carly M Farrell, et al.
Nature Communications|May 25, 2026
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trialJeffrey S Johnson, Justin W Miller, Firas Hatoum, et al.
Blood Cancer Discovery|April 16, 2021
TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemiaSeongseok Yun, Nicole D Vincelette, Xiaoqing Yu, et al.
Journal of the National Cancer Institute|November 29, 2015
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaShiv K Gupta, Sani H Kizilbash, Brett L Carlson, et al.
Pageof 8